An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of AZD1775 for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2018
At a glance
- Drugs Adavosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 May 2018 Planned number of patients changed from 42 to 52.
- 26 Mar 2018 Planned number of patients changed from 48 to 42.
- 23 Nov 2017 Status changed from not yet recruiting to recruiting.